Peculiarities of granulocyte-macrophage and macrophage colony-stimulating factors receptors expression in subpopulations of peripheral blood monocytes of patients with chronic obstructive pulmonary disease

Introduction. To analyze of the severity of respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD), depending on the presence of an exacerbation or novel coronavirus infection (NCVI), taking into account the activity of acute phase blood parameters.
Materials and methods. The medical documentation of 162 patients with COPD was studied, which were divided into 3 groups: group 1 (n=61) ‒ COPD and NCVI, group 2 (n=53) – stable COPD, group 3 (n=48) ‒ COPD exacerbation. The severity of respiratory symptoms was assessed using points. To assess the activity of inflammation the following biochemical indicators were used ‒ C-reactive protein (CRP) and fibrinogen (g/L).
Results. According to the severity of cough and the intensity of dyspnea on the mMRC scale, the first, second and third groups did not differ statistically (p=0.07). Patients of the first group (82.5%) characterized by the absence of classical criteria for exacerbation of COPD. In terms of the severity of sputum production, the first, second and third groups are statistically different (p=0.0001). The first, second and third groups differ significantly in the level of serum CRP (p=0.0001) and fibrinogen (p=0.009). According to the results of the correlation analysis, some relationships found between respiratory symptoms and the level of CRP and fibrinogen.
Conclusion. The clinical feature of the associated course of stable COPD and NCVI is the presence of severe dyspnea and the absence of classic criteria for exacerbation of COPD. Systemic inflammation in NCVI and stable COPD are more pronounced than in isolated stable COPD or exacerbation and correlates with cough and dyspnea. Practitioners for the differential diagnosis of NCVI in stable COPD can use the data obtained.

1. Kapellos T.S., Bassler K., Aschenbrenner A.C., Fujii W., Schultze J.L. Dysregulated functions of lung macrophage populations in COPD. J. Immunol. Res. 2018; 2018:2349045. https://doi.org/10.1155/2018/2349045

2. Gershon A.S., Warner L., Cascagnette P., Victor J.C., To T. Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 2011; 378(9795):991–996. https://doi.org/10.1016/S0140-6736(11)60990-2

3. Lopez-Campos J.L., Tan W., Soriano J.B. Global burden of COPD. Respirology 2016; 21(6):14–23. https://doi.org/10.1111/resp.12660

4. Corrigan C.J., Kay A.B. The roles of inflammatory cells in the pathogenesis of asthma and of chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1991; 143(5Pt1):1165–1168. https://doi.org/10.1164/ajrccm/143.5_Pt_1.1165

5. Chung K.F. Cytokines in chronic obstructive pulmonary disease. Eur. Respir. J. Suppl. 2001; 34:50s–59s.

6. Grage-Griebenow E., Flad H.D., Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J. Leukoc. Biol. 2001; 69(1):11–20. https://doi.org/10.1189/jlb.69.1.11

7. Hume D.A., Ross I.L., Himes S.R., Sasmono R.T., Wells C.A., Ravasi T. The mononuclear phagocyte system revisited. J. Leukoc. Biol. 2002; 72(4):621–627. https://doi.org/10.1189/jlb.72.4.621

8. Auffray C., Sieweke M.H., Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 2009; 27:669–692. https://doi.org/10.1146/annurev.immunol.021908.132557

9. Cornwell W.D., Kim V., Fan X., Vega M.E., Ramsey F.V., Criner G.J., Rogers T.J. Activation and polarization of circulating monocytes in severe chronic obstructive pulmonary disease. BMC Pulm. Med. 2018; 18(1):101. https://doi.org/10.1186/s12890-018-0664-y

10. Martinez F., Gordon S., Locati M., Mantovani A. Transcriptional Profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 2006; 177(10):7303–7311. https://doi.org/10.4049/jimmunol.177.10.7303

11. Martinez F., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009; 27:451–483. https://doi.org/10.1146/annurev.immunol.021908.132532

12. Hamilton J.A., Achuthan A. Colony stimulating factors and myeloid cell biology in health and disease. Trends Immunol. 2013; 34(2):81–89. https://doi.org/10.1016/j.it.2012.08.006

13. Hamilton J.A. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 2008; 8(7):533– 544. https://doi.org/10.1038/nri2356

14. Ushach I., Zlotnik A. Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage. J. Leukoc. Biol. 2016; 100(3): 481–489. https://doi.org/10.1189/jlb.3RU0316-144R

15. Trus E, Basta S, Gee K. Who's in charge here? Macrophage colony stimulating factor and granulocyte macrophage colony stimulating factor: Competing factors in macrophage polarization. Cytokine 2020; 127:154939. https://doi.org/10.1016/j.cyto.2019.154939

16. Wong K.L., Tai J.J., Wong W.C., Han H., Sem X., Yeap W.H., Kourilsky P., Wong S.C. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011; 118(5):e16–31. https://doi.org/10.1182/blood-2010-12-326355

17. Evren E., Ringqvist E., Tripathi K.P., Sleiers N., Rives I.C., Alisjahbana A., Gao Y., Sarhan D., Halle T., Sorini C., Lepzien R., Marquardt N., Michaëlsson J., Smed-Sörensen A., Botling J., Karlsson M.C.I., Villablanca E.J., Willinger T. Distinct developmental pathways from blood monocytes generate human lung macrophage diversity. Immunity 2021; 54(2):259–275.e7. https://doi.org/10.1016/j.immuni.2020.12.003

18. Olingy C.E., San Emeterio C.L., Ogle M.E., Krieger J.R., Bruce A.C., Pfau D.D., Jordan B.T., Peirce S.M., Botchwey E.A. Non-classical monocytes are biased progenitors of wound healing macrophages during soft tissue injury. Sci. Rep. 2017; 7(1):447. https://doi.org/10.1038/s41598-017-00477-1